Hyperphosphatemia and hyperparathyroidism in incident chronic kidney disease patients

被引:19
|
作者
Ramos, Ana M. [1 ]
Albalate, Marta [1 ]
Vazquez, Silvia [2 ]
Caramelo, Carlos [1 ]
Egido, Jesus [1 ]
Ortiz, Alberto [1 ]
机构
[1] Autonomous Univ Madrid, Jimenez Diaz Fdn Capio, Nephrol & Hypertens Unit, E-28049 Madrid, Spain
[2] Autonomous Univ Madrid, Jimenez Diaz Fdn Capio, Stat Unit, E-28049 Madrid, Spain
关键词
chronic kidney disease; bone mineral metabolism; PTH; hyperphosphatemia;
D O I
10.1038/ki.2008.543
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Disturbances in bone and mineral metabolism are common in chronic kidney disease (CKD) patients. Most studies have been performed in hemodialysis and there is less information on non-dialysis patients, on the coexistence of other risk factors and on the achievement of more recent and stringent guidelines. Cross sectional study of analytical mineral and bone parameters in 125 incident patients (creatinine clearance <60 ml/min) in a monographic CKD clinic. Evaluation after one year of follow-up in 69 patients. Progression of CKD was associated with significant increased levels of phosphate, calcium x phosphate and iPTH and decreased calcium and 1,25 dihydroxyvitamin D. Levels of 25-hydroxyvitamin D were unchanged, but lower than recommended. Phosphate correlated negatively with 1,25-dihydroxyvitamin D and creatinine clearance, and positively with iPTH. At every stage of CKD, most patients had PTH values outside recommended limits. More than 69% CKD 3 and CKD 4 patients had higher than recommended PTH levels. Above recommended phosphate levels were present in 25% of CKD 4 and 47% of CKD 5 patients. Most of these had associated high LDL-cholesterol. Higher than recommended calcium levels were more prevalent than low calcium and there was a high prevalence (31%) of vascular calcification. One year of intervention improved the percentage of patients with controlled calcium or iPTH, but not phosphate. In incident CKD patients there is a high prevalence of out-of-target mineral and bone analytical parameters. The currently authorized therapeutic arsenal for these patients may not be adequate to deal with the problem.
引用
收藏
页码:S88 / S93
页数:6
相关论文
共 50 条
  • [21] Calcifediol to treat secondary hyperparathyroidism in patients with chronic kidney disease
    Galassi, Andrea
    Bellasi, Antonio
    Ciceri, Paola
    Pivari, Francesca
    Conte, Ferruccio
    Cozzolino, Mario
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (10) : 1073 - 1084
  • [22] Hyperparathyroidism in chronic kidney disease patients: an update on current pharmacotherapy
    Fukagawa, Masafumi
    Komaba, Hirotaka
    Kakuta, Takatoshi
    EXPERT OPINION ON PHARMACOTHERAPY, 2013, 14 (07) : 863 - 871
  • [23] Hyperuricemia is associated with secondary hyperparathyroidism in patients with chronic kidney disease
    Tiago Emanuel M. Costa
    Julia C. Lauar
    Mariana L. R. Innecchi
    Venceslau A. Coelho
    Rosa M. A. Moysés
    Rosilene M. Elias
    International Urology and Nephrology, 2022, 54 : 2255 - 2261
  • [24] Cardiovascular Complications of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease
    Eller, K.
    JOURNAL FUR MINERALSTOFFWECHSEL, 2014, 21 (01): : 10 - 13
  • [25] Pharmacological Management of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease
    Salam, S. N.
    Khwaja, A.
    Wilkie, M. E.
    DRUGS, 2016, 76 (08) : 841 - 852
  • [26] New developments in the management of hyperphosphatemia in chronic kidney disease
    McIntyre, Christopher W.
    SEMINARS IN DIALYSIS, 2007, 20 (04) : 337 - 341
  • [27] Strategies aiming to control hyperphosphatemia in chronic kidney disease
    Torres, Pablo Antonio Urena
    NEPHROLOGIE & THERAPEUTIQUE, 2017, 13 : S95 - S101
  • [28] A new approach to the evaluation of hyperphosphatemia in chronic kidney disease
    Savica, V.
    Calo, L. A.
    Granata, A.
    Caldarera, R.
    Cavaleri, A.
    Santoro, D.
    Monardo, P.
    Savica, R.
    Muraca, U.
    Bellinghieri, G.
    CLINICAL NEPHROLOGY, 2007, 68 (04) : 216 - 221
  • [29] Depression and incident cardiovascular disease among patients with chronic kidney disease
    D'Oro, Anthony
    Patel, Devansh Himanshu
    Wass, Sojin
    Dolber, Trygve
    Nasir, Khurram
    Dobre, Mirela
    Rahman, Mahboob
    Al-Kindi, Sadeer
    INTERNATIONAL JOURNAL OF CARDIOLOGY CARDIOVASCULAR RISK AND PREVENTION, 2023, 18
  • [30] Increased extraosseus 99m-technetium hydroxy diphosphonate uptake in chronic kidney disease patients with secondary hyperparathyroidism. Correlation with hyperphosphatemia
    Enevoldsen, L. H.
    Heaf, J.
    Hasbak, P.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2010, 37 : S471 - S471